19 results
424B3
CNTX
Context Therapeutics Inc.
12 Apr 22
Prospectus supplement
4:14pm
;
restrictions on sale, distribution or use;
product establishment, registration and listing requirements and reporting requirements;
recall requirements … , including a mandatory recall if there is a reasonable probability that a product would cause serious adverse health consequences or death;
an order
POS AM
CNTX
Context Therapeutics Inc.
4 Apr 22
Prospectus update (post-effective amendment)
5:08pm
;
restrictions on sale, distribution or use;
product establishment, registration and listing requirements and reporting requirements;
recall requirements … , including a mandatory recall if there is a reasonable probability that a product would cause serious adverse health consequences or death;
an order
10-K
2021 FY
CNTX
Context Therapeutics Inc.
23 Mar 22
Annual report
4:17pm
;
recall requirements, including a mandatory recall if there is a reasonable probability that a product would cause serious adverse health … include any of the following sanctions:
warning letters, untitled letters, Form 483s, fines, injunctions, consent decrees and civil penalties;
recall
424B4
CNTX
Context Therapeutics Inc.
17 Dec 21
Prospectus supplement with pricing info
8:00am
and reporting requirements;
recall requirements, including a mandatory recall if there is a reasonable probability that a product would cause serious … penalties;
recall or seizure of products;
operating restrictions, partial suspension or total shutdown of production;
the FDA’s refusal of requests
424B4
x73ujbj6qvtg2
20 Oct 21
Prospectus supplement with pricing info
5:05pm
S-1
kpvfeu8e 3p
27 May 21
IPO registration
5:28pm
S-1
EX-10.1
8wv6c
27 May 21
IPO registration
5:28pm
DRS/A
EX-10.1
zhvyo740pi5ucf1ezaa
3 May 21
Draft registration statement (amended)
12:00am
DRS/A
5g8z ezedmpwldr9qb
3 May 21
Draft registration statement (amended)
12:00am
DRS
oiz7m85
22 Mar 21
Draft registration statement
12:00am
- Prev
- 1
- Next